Bortezomib will increase the stage or impact of flibanserin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe. Increased flibanserin adverse effects may perhaps arise if coadministered with several weak CYP3A4 inhibitors. Other results, like a skin rash, may not be critical but might cause issue. Some effects might not manifest https://johnathanntyci.blogs-service.com/57732721/what-does-lp-pla2-in-1-mean